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D ementia is a large and growing health problem indeveloped and developing countries, with total costs
approaching 1% of global gross domestic product, threatening
the sustainability of healthcare systems.1 There are currently
no disease-modifying treatments for the most common cause
of dementia, Alzheimer disease (AD). The second most
common contributor to dementia risk is cerebrovascular
disease.2 In contrast to AD, there is greater hope that
vascular contributions to cognitive impairment can be
prevented and treated. Recent evidence that the incidence
of dementia is declining has prompted speculation, not yet
conﬁrmed, that this decline may be partly attributable to
improved vascular care.3,4
In this article, we review trial design and drug development
for vascular cognitive impairment (VCI), focusing on symp-
tomatic patients with vascular mild cognitive impairment
(MCI) or dementia. First, we review axes along which vascular
components of cognitive impairment can be addressed,
including choice of trial population, trial intervention, and
type of outcome. Second, we brieﬂy review the pathophys-
iology of VCI, introducing the concept that trials may focus on
disease modiﬁcation, improving resilience, or enhancing
cognition. Third, we systematically review prior drug trials
for VCI patients according to drug class and trial size. Finally,
we offer suggestions for methodological improvements for
future trials.
Trial Design Choices
The effectiveness of treating vascular contributions to
dementia would be best proved by randomized controlled
trials (RCTs). Trials addressing the vascular contributions to
cognitive impairment and neurodegeneration may target a
speciﬁc population with VCI or at risk for VCI, a vascular
intervention, or VCI as an outcome (Figure 1).
Patients with clinically diagnosed symptomatic VCI are an
obvious target population (Figure 1A), and the primary focus
of this review. The terms VCI, vascular contributions to
cognitive impairment and dementia, vascular cognitive
disorders, and vascular neurocognitive disorders all describe
circumstances in which cognitive impairment or dementia is
partly or primarily causally related to vascular disease.
Recent clinical diagnostic criteria for VCI,5 vascular cognitive
disorders,6 and vascular neurocognitive disorder7 are con-
ceptually similar; henceforth, in this review we will use the
term VCI to refer to these diagnostic entities. All of the VCI
criteria rely on clinical evidence of a cognitive impairment
syndrome (subdivided as MCI or dementia), clinical evidence
of cerebrovascular disease (most commonly, history of
stroke or neuroimaging evidence of severe clinically unap-
parent cerebrovascular disease), and a clinical judgment that
the cerebrovascular disease is causing the cognitive impair-
ment. The clearest circumstance is where there is a stroke
that is immediately followed by new cognitive impairment;
however, VCI attributable to “silent,” or more properly
covert, cerebrovascular disease is actually more common.
The term VCI also encompasses the common clinical
scenario where cerebrovascular disease is accompanied by
comorbid pathologies including AD and other neurodegener-
ative pathologies, which has been termed multiple etiology
or “mixed” dementia.
VCI trials may also be deﬁned based on application of an
intervention to reduce vascular risk—whether to improve
vascular function, prevent cerebrovascular disease, or prevent
cerebrovascular injury (Figure 1B). The list of interventions
that could be considered “vascular” in nature is quite broad
when one considers all interventions whose effect may be
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wholly or partly mediated by improving vascular health.
Examples could include blood pressure lowering, other forms
of vascular risk factor reduction, or physical exercise. These
interventions could be applied to the general population or to
groups of patients at high risk for VCI. Such high-risk groups
could even include patients clinically diagnosed with other
forms of neurodegeneration such as AD, given that multiple
etiology dementia with a vascular component is the most
common neuropathology of dementia,8 and that cerebrovas-
cular function and disease have been hypothesized to
promote AD pathology.9
Finally, VCI trials may be based on an expectation of
preventing symptomatic VCI (Figure 1C). Many such trials
deﬁne patient eligibility based on clinically deﬁned cere-
brovascular syndromes (eg, stroke) or radiological evidence of
silent cerebrovascular disease, with or without cognitive
impairment. This would include trials of cognitive rehabilita-
tion after stroke where cognitive rehabilitation is provided to
all stroke patients regardless of the baseline presence or
absence of clinical VCI. Given the clinical difﬁculty in
determining the causes of cognitive impairment and neu-
ropathological evidence that the most common cause of
dementia is not pure pathology in any form but rather
multiple-etiology dementia,8 it would be best for such trials to
include all-cause dementia or mixed dementia as outcomes,
rather than restrict the outcome to clinically diagnosed pure
vascular dementia.
Pathophysiology of VCI: Implications for
Therapeutic Development
Modern understanding of cerebrovascular function is based on
the concept of a tightly integrated neurovascular unit.10 The
role of the vasculature is to regulate perfusion to the tissue,
responding to changes in neuronal activity, systemic perfusion
pressure, and local changes to the chemical environment
including partial pressure of carbon dioxide. Signaling by
astrocytes, pericytes, and endothelium regulates arterial
smooth muscle tone to deliver the appropriate amounts of
oxygen and glucose to the brain.10 There is increasing evidence
that the vasculature also plays a key role in waste product
removal from the brain, including soluble abeta.11
When the vasculature becomes diseased, cerebrovascular
injury to the brain may follow. Many, but not all, types of
cerebrovascular injury may be detected using magnetic
resonance imaging (MRI).12 Cerebral infarction and hemor-
rhage are the most destructive forms of injury, and may cause
clinically evidence stroke syndromes. However, most cerebral
infarctions are actually clinically unrecognized, or more
accurately are associated with clinically hard to detect
cognitive impairments.13 Thus, the estimated incidence and
prevalence of MRI-deﬁned infarcts are more than 5-fold higher
than for symptomatic stroke.14 The prevalence of MRI-
invisible microinfarcts, which are tiny 50 to 200-lm-diameter
infarcts below the spatial resolution of MRI but visible
Figure 1. Trial design considerations categorized by population (A), intervention (B), and
outcome (C). AD indicates Alzheimer disease; CADASIL, cerebral autosomal dominant
arteriopathy with subcortical ischemic leukoencephalopathy; MCI, mild cognitive impair-
ment; VCI, vascular cognitive impairment .
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microscopically at autopsy, is even higher; they are detected
neuropathologically inabout40%ofall patientswithdementia.15
As silent cerebral infarcts accrue over time, cognitive
impairment worsens and risk for dementia increases.16
Other forms of detectable cerebrovascular injury include
white matter lesions of presumed vascular origin, microb-
leeds, dilated perivascular spaces, and atrophy.12 White
matter lesions of presumed vascular origin are readily
detectable as white matter hyperintensity (WMH) on MRI,
and are associated with increased risk for dementia. Although
associated with vascular risk factors such as hypertension
and cerebrovascular diseases such as cerebral autosomal
dominant arteriopathy with subcortical ischemic leukoen-
cephalopathy, the pathophysiology of WMH remains some-
what unclear and may be multifactorial.17
To treat vascular contributions to cognitive impairment and
neurodegeneration, VCI therapeutic strategies could aim to
reduce the build-up of cerebrovascular injury, improve neu-
rovascular unit function, or enhancecerebral resilience to injury.
Disease-modifying therapies (ie, those that reduce theaccrual of
cerebrovascular injury) hold the most promise for public health
impact because they would treat VCI at its source. However, to
date the most success has been obtained with symptomatic
treatments (ie, those that improve function or cognitive
resilience without affecting the rate of disease progression).
Reducing the build-up of neurovascular injury could be
accomplished by treating conventional vascular risk factors or
by exploiting as-yet unidentiﬁed, new molecular targets
arising from research on the response of the neurovascular
unit to vascular pathology. These trials will require longer
durations or larger sample sizes to accrue sufﬁcient numbers
of new events such as incident infarcts.
Improving neurovascular unit function could restore better
regulation of cerebral blood ﬂow delivery to meet tissue
metabolic needs. This restoration of homeostasis could
theoretically improve function of ischemic neurovascular
units in the short term, potentially requiring trials of only
short duration to show improved outcomes. However, it
remains controversial whether ischemia impairs cognition in
the absence of infarction.18
Enhancing cerebral resilience to injury could be accom-
plished by making cells more resistant to hypoxia and ischemia
(ie, neuroprotection), enhancing neuronal plasticity in the face
of an injury, or increasing cognitive reserve so that future
cerebrovascular brain injury is better tolerated. Enhancing
cognitive reserve could potentially be accomplished by
increasing neuronal plasticity, developing or retaining more
numerous synaptic connections, or enhancing neuronal net-
work function through interventions such as cognitive training,
cognitive rehabilitation, lifestyle and behavior modiﬁcation (eg,
physical exercise), neurostimulation (eg, by transcranial direct
current or magnetic stimulation), or drugs.
Drug Development
Our review of drug development is based on a systematic
review of all published RCTs in patients clinically diagnosed
with VCI. RCTs in patients with VCI were identiﬁed by a search
of ALOIS, an open access online database of all RCTs for
cognitive impairment maintained by the Cochrane Collabora-
tion Dementia and Cognitive Impairment Group (www.medic
ine.ox.ac.uk/alois). The “health status/diagnosis” ﬁeld was
searched on October 12, 2016, using keywords “vascular,”
“infarct,” “stroke,” “ischemic,” “mixed,” “Binswanger,” and
“circulation.” Two reviewers determined eligibility by consen-
sus and abstracted data using standardized forms, and a third
reviewer was added to resolve disagreements. RCTs were
included if they described a randomized intervention to
improve cognitive, behavioral, or functional outcomes in a
patient population with VCI or mixed dementia with VCI
diagnosed by standard criteria or by the study author’s own
criteria. Studies were excluded if outcomes were not reported
separately for the patients with VCI or mixed dementia. Non-
English studies were included and read by native language
speakers. Study quality was assessed using the Cochrane
Risk of Bias Tool.19 More details on the review are available at
the International Prospective Register of Systematic Reviews
(PROSPERO ID CRD42016037958) at http://www.crd.yor
k.ac.uk/PROSPERO. Institutional Review Board approval was
not required because this was a systematic review.
We identiﬁed 130 previously published RCTs in which
patients with VCI were treated with pharmacologic or
nonpharmacologic interventions and followed for cognitive,
behavioral, or functional outcomes (Figure 2). RCTs over time,
classiﬁed by intervention type, are shown in Figure 3. Most
RCTs included patients with vascular dementia, with only a
few (7/130, 5.4%) restricted to patients with MCI or
cognitively impaired but nondemented participants. Most
included a placebo comparator (88/130, 68%). Most trials
were of drugs; only a minority (14/130, 11%) tested
nonpharmacological strategies. A diverse array of pathophys-
iological processes was targeted by drug types including
vasodilators, neurotransmitter modulators, neurotrophic
drugs, platelet antiaggregants, and antioxidants.
There were a larger number of individual trials reported in
the 1980s and 1990s, but a larger number of patients
randomized in the 2000s (Figure 3). Trials in the 1980s and
1990s predominantly tested drugs aimed at improving
perfusion through vasodilation and other strategies reﬂecting
the historical concept that cerebrovascular insufﬁciency could
be reversed by increasing cerebral blood ﬂow, while the later,
larger-scale trials predominantly tested cognitive-enhancing
cholinesterase inhibitors and memantine.
Individual drugs, categorized by maximum phase of
development, are shown in Figure 4. Four drug classes
DOI: 10.1161/JAHA.117.005568 Journal of the American Heart Association 3
Vascular Dementia Clinical Trials Smith et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
proceeded to phase 3 RCTs: cholinesterase inhibitors,
memantine, naftidrofuryl, and propentofylline.
The cholinesterase inhibitors reduce synaptic breakdown
of the neurotransmitter acetylcholine, enhancing cholinergic
transmission. They were originally developed in response to
basic research showing a cholinergic deﬁcit in patients with
AD dementia. Subsequent work suggests that cerebrovascular
injury also damages cholinergic pathways.20 Three cholines-
terase inhibitors were tested in phase 3 trials of patients with
vascular dementia or mixed dementia—donepezil,21–23 galan-
tamine,24,25 and rivastigmine26—and the results have been
pooled and analyzed by the Cochrane collaboration.27–29 All of
the phase 3 RCTs were 6 months in duration, and NINDS-
AIREN (National Institute of Neurological Disorders and Stroke
and the Association Internationale pour la Recherche et
l’Enseignement en Neurosciences) criteria30 were used to
diagnose vascular dementia. All trials used the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog), or variants
incorporating additional tests of executive function, as the
primary cognitive measure, along with scales for global
impression of change or activities of living. All of the trials
reported positive effects on the ADAS-Cog score (or variants);
however, the absolute degree of beneﬁt (2 points) was only
about half of what was seen in AD trials (3–4 points) with
the same durations and end points.31 Results on scales of
global impression of change were mixed, with some RCTs
reporting positive effects27 but others reporting no differ-
ence,23,25,26 and 1 trial reported no difference in AD
Cooperative Study–Activities of Daily Living Inventory.24
Additionally, the cholinesterase inhibitor donepezil was
studied in a RCT in patients with cerebral autosomal dominant
arteriopathy with subcortical ischemic leukoencephalopathy
and cognitive impairment or dementia.32 In this study, 168
patients with cerebral autosomal dominant arteriopathy with
subcortical ischemic leukoencephalopathy were randomized
to donepezil 10 mg per day or placebo for 18 weeks. The
primary outcome was the V-ADAS-Cog. The difference in
V-ADAS-Cog scores (0.4 points) was not signiﬁcant, and
donepezil treatment resulted in better cognitive test scores on
only 1 of multiple secondary outcomes, the Trail-Making test
parts A and B.
Memantine is an N-methyl-D-aspartate antagonist used as
symptomatic therapy in moderate-to-severe AD. It has been
tested in 2 trials of 28 weeks of treatment of patients with
vascular dementia by NINDS-AIREN criteria.33,34 In 1 trial with
321 patients, memantine treatment resulted in better ADAS-
Cog scores (2.0 point difference) but no difference in the
proportion with improvement or no change in the Clinician’s
Interview-Based Impression of Change Plus Caregiver Input
(60% versus 52%).33 In the second trial of 579 patients,
memantine treatment resulted in better ADAS-Cog scores
(1.8 point difference, P<0.001) but no difference in the
Clinician Global Impression of Change.34 The results of these
2 RCTs have been pooled and meta-analyzed by the Cochrane
group.35
Naftidrofuryl is a serotonin 5-HT2 receptor antagonist with
vasodilator properties, which has also been used as a
treatment for peripheral claudication. It was tested in 4 RCTs
in patients with vascular or mixed dementia with sample sizes
of 6, 27, 108, and 339 participants.36–39 The largest study
was a 6-month trial of 2 doses (400 mg per day and 600 mg
per day) compared to placebo in patients meeting NINDS-
AIREN criteria for vascular dementia or mixed dementia.39 The
primary outcome was the proportion of patients without any
decline in either ADAS-Cog or Sandoz Clinical Assessment
Geriatric Scale at 6 months compared to baseline. The
proportions without any decline were 58% for placebo, 75%
for the 400-mg dose (P=0.005 versus placebo), and 73% for
the 600-mg dose (P=0.02 versus placebo). Mean differences
were not provided.
Propentofylline is a phosphodiesterase inhibitor and adeno-
sine reuptake inhibitor with vasodilator properties. Results
have been reported from 3 studies with 30, 90, and 359
Figure 2. Flow chart showing study selection. ALOIS indicates
the Cochrane Dementia and Cognitive Improvement Group’s
Specialized Register; VCI, vascular cognitive impairment.
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participants.40–42 The largest study reported a pooled analysis
of data from 4 individual RCTs with a total of 359 participants
with vascular dementia diagnosed by NINDS-AIREN criteria.
These participants were randomized to propentofylline 600 mg
per day versus placebo for either 6 or 12 months. Primary
outcomes were not deﬁned, but signiﬁcant results at the ﬁnal
visit favoring propentofylline were reported for the Mini-Mental
State Examination (0.9-point difference, P<0.01), Gottfries–
Brain–Steen scale (3.5-point difference, P<0.01), and Clinical
Global Improvements (0.7 point difference, P<0.01) but not the
syndrome short test (0.7-point difference) or the Nurnberger–
Alters–Beobachtungs–Skala for activities of living (0.1 point
difference). Methodological problems with the reporting of this
pooled individual patient meta-analysis include lack of detail on
the conduct of the individual RCTs, lack of a speciﬁed primary
outcome, and insufﬁcient information on completeness of
follow-up. Baseline and follow-up data from a subsequent
phase 3 trial of propentofylline (MN-305) in patients with
possible or probable vascular dementia according to NIND-
S-AIREN criteria were described in a subsequent review but the
results of the placebo comparison were not provided43 and the
sponsoring pharmaceutical company refused to provide the
trial results to the Cochrane Collaboration.44 Consequently, the
efﬁcacy of propentofylline for vascular dementia is uncertain,
and a risk for bias cannot be excluded in the published partial
results.
In summary, the cholinesterase inhibitors advanced the
farthest along the path to regulatory approval in the United
States, Canada, and Europe but ultimately failed to receive
approval. Concerns over the use of cholinesterase inhibitors
for VCI have included the lower effect sizes compared to AD;
the inconsistent beneﬁts on clinical global impression,
activities of daily living, and neuropsychiatric symptoms; and
the possibility that cholinesterase inhibition may be improving
symptoms of clinically unrecognized accompanying AD rather
than VCI. Consensus groups convened by the American Heart
Association and Canadian Stroke Best Practices recommend
that cholinesterase inhibitors could be considered for use in
VCI patients but with only intermediate-grade evidence,5,45
while the fourth Canadian Consensus Conference on the
Diagnosis and Treatment of Dementia recommends against
using cholinesterase inhibitors in VCI patients unless there is
comorbid AD.46
Paradoxically, most of the RCTs we reviewed (109/130,
84%) claimed efﬁcacy on 1 or more trial outcomes even
though most did not progress to later phase studies and
none have received regulatory approval. There are likely
multiple reasons for this paradox. Most past trials were
Figure 3. Published randomized controlled trials of pharmacological and nonpharmacological treatments for VCI.
Data were abstracted from 130 eligible trials. The area of the bubble is linearly proportional to the total randomized
sample size. Bubbles are color coded according to the presumed mechanism of action. “Multiple” indicates that the
trial compared drugs or strategies with more than 1 mechanism, with or without an additional untreated control
group. Nonpharmacological strategies included group therapy, acupuncture, and transcranial magnetic stimulation
or direct current stimulation. NMDA, N-methyl-D-aspartate.
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small (median randomized sample size 58, interquartile
range 31–112) and short duration (median 84 days, 91/123
[74%] that reported duration were less than 24 weeks),
many (78/130, 60%) did not analyze activities of living, and
none analyzed progression from MCI to dementia. With
these trial designs it is difﬁcult to predict which candidate
drugs are likely to have durable or disease-modifying effects.
Patient populations were heterogeneous with respect to
diagnostic criteria and disease stage, particularly before
publication of the NINDS-AIREN criteria. Many trials did not
require neuroimaging conﬁrmation of cerebrovascular dis-
ease (67/130, 51%). Outdated trial designs make most of
the previously published results vulnerable to bias, partic-
ularly those published before 2000. Commonly encountered
methodological limitations included lack of prespeciﬁed
primary outcomes, multiple hypothesis testing without
appropriate adjustment, incomplete accounting of loss to
follow-up, and lack of intent-to-treat analysis, all of which
predispose to false-positive results.
A review of the clinicaltrials.gov trial registry (accessed
June 6, 2016) revealed several ongoing or planned trials in
patients with VCI. Among 10 RCTs that are listed as
actively recruiting, trial interventions include cholinesterase
inhibitors (NCT02660983, NCT02444637, NCT02098824),
exercise (NCT02669394, NCT02550990), herbal
medications (NCT02641886, NCT02453932), cognitive train-
ing (NCT02640716), hyperbaric oxygen (NCT02085330), and
specialty vascular clinic care (NCT01924312).
Nonpharmacological Treatments for VCI
A smaller number of trials (16/130, 12%) included nonphar-
macological therapies as a comparator arm. Interventions
tested were acupuncture or acupressure (3), electroacupunc-
ture (2), reminiscence therapy (3), transcranial direct stimu-
lation (3), sensory stimulation (1), transcranial magnetic
stimulation (1), heparin-induced extracorporeal low-density
lipoprotein precipitation (1), moxibustion (a traditional Asian
medical therapy that involves burning the herb mugwort on
the skin; 1), and carotid endarterectomy (1). Many of these
trials originated in East Asia including China, Japan, and Korea
(12/16). The studies were generally small (median 38
patients, range 7–180 patients) and of short duration (median
56 days; only 2 were longer than 90 days).
New Opportunities for Trials in VCI
Our view is that the time is ripe for a new generation of VCI
trials exploiting advances in diagnosis, outcome
Figure 4. Drug development status of medications for patients with vascular cognitive
impairment. Phase III was operationally deﬁned retrospectively as randomized controlled
trials with ≥300 participants, later phase II as ≥100 to 299 participants, and early phase II
as <100 participants. Data from trials with untreated controls (mostly receiving a placebo)
were used to generate the ﬁgure. A single large trial (>300 participants) of the calcium
channel blockers nicardipine vs clentiazem was not included because there was no
untreated control arm.
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measurement, neuroimaging biomarkers, and trial design
methodology, and a growing understanding of the pathobiol-
ogy of vascular contributions to neurodegeneration (Table).
Trials should aim to improve cognition, daily function, and
quality of life by targeting speciﬁc, prespeciﬁed mechanisms
of impairment using appropriate diagnostic criteria and, when
available, appropriate biomarkers for patient identiﬁcation,
target engagement, and outcomes. It is important to
recognize that VCI is a syndrome, not a disease. Essentially
any cerebrovascular disease that destroys brain can lead to
VCI. Trial interventions should target not just a diagnostic
syndrome but rather a speciﬁc mechanism of disease,
brain injury, accommodation, or recovery in an appropriate
population.47
Patient Selection
Patients should be selected using modern diagnostic criteria
with neuroimaging conﬁrmation of cerebrovascular disease or
related brain injury.5–7 The Standards for Reporting Vascular
Changes on Neuroimaging provides consensus deﬁnitions for
infarcts, WMHs of presumed vascular origin, microbleeds,
enlarged perivascular spaces and brain atrophy, as well as
suggestions for MRI acquisition protocols.12 Further validation
work on the reliability of these criteria and standards in
clinical and research practice would be welcome.
VCI caused by cerebral small vessel disease may be the
most important target for future RCTs. Reducing the
progression of cerebral small vessel disease and its impact
on cognition and risk for dementia would produce large
public health beneﬁts. Neuropathology studies show that
cerebral small vessel disease, predominantly in the absence
of a clinical history of stroke, is found in most cases of
dementia.48 It accounts for approximately one quarter to one
third of the population-attributable risk for dementia.49,50
The majority of cerebral small vessel disease is caused by
arteriolosclerosis because of aging, hypertension, and con-
ventional vascular risk factors, while a minority is caused by
vascular beta-amyloid deposition (that is, cerebral amyloid
angiopathy). The International Society for Vascular Behav-
ioral and Cognitive Disorders has offered neuroimaging
criteria for cerebral small vessel disease sufﬁcient to cause
vascular MCI or dementia.6 Further reﬁnement and validation
of neuroimaging criteria for vascular MCI and dementia
would be helpful.
Vascular MCI may represent an ideal stage to intervene
before accrual of irreversible disability. Because it is clinically
difﬁcult to discriminate MCI from very early dementia given
that “generally mild functional impairment for complex tasks”
is typically already apparent in MCI,51 it would also be
reasonable to alternatively target early cognitive impairment
based on cognitive concerns, low cognitive test scores, and
Table. Considerations for Improving the Quality of Trials in Patients With VCI
Consideration Potential Strategies
Include clearly defined populations
with VCI 1. Use modern VCI diagnostic criteria
2. Require neuroimaging evidence of cerebrovascular disease as an inclusion criterion, with central adjudication
3. When interactions with AD pathology are hypothesized, incorporate markers of the AD pathophysiological process
Use clearly defined clinically
relevant end points 1. Include measures of cognitive function and activities of living
2. Prespecify primary outcome and analysis plan
3. Plan trial duration according to mechanism of effect: trials to prevent cerebrovascular disease progression may
require longer duration than trials of cognitive/functional enhancement
4. For trials of cognitive/functional enhancement, when appropriate include assessments of persistence of effect after
active intervention ceases
5. Include neuropsychological measures of executive function
Consider use of biomarkers where
appropriate 1. When available, include biomarkers of on-target intervention effects
2. Further develop and validate biomarkers that may serve as monitoring biomarkers or surrogate end points in early
phase trials
Improve quality of trial design and
reporting 1. Adhere to Consolidated Standards of Reporting Trials (CONSORT)
Explore new potential therapeutic
avenues 1. Develop and refine animal models of cerebral small vessel disease, cerebral amyloid angiopathy, large artery disease,
and other vascular cognitive disorders
2. Explore potential new therapeutic targets using translational approaches (eg, inflammation, oxidation, solute
clearance, and restoring normal cerebral blood flow regulation)
AD indicates alzheimer disease; VCI, vascular cognitive impairment.
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preserved basic activities of living. Trials may also target pre-
MCI populations with neuroimaging evidence of cerebrovas-
cular disease; however, deﬁnitive clinical trials will require
larger sample size or longer durations to accrue enough
clinical events, such as detectable cognitive decline or
progression to dementia.
Trials must be designed with the awareness that most
patients have multiple etiology dementia.8 Seeking patients
with pure VCI for RCTs may be fruitless as few patients will
be eligible, recruitment will be slow, and the trial results will
not be generalizable to most patients with cognitive
disorders. Instead, we suggest that eligibility should be
based on ruling in VCI by neuroimaging without necessarily
excluding the concomitant presence of other neuropatholo-
gies including AD. Whether to also assess for the presence
or absence of AD pathology as a modiﬁer of treatment
effects depends on the nature of the intervention and the
resources available. Cerebrospinal ﬂuid and positron emis-
sion tomography markers of the AD pathophysiological
process are expensive and invasive, respectively, and
probably not feasible for most trials in VCI. Fortunately,
assessment of AD pathology is not necessary to obtain
unconfounded estimates of treatment effects because
unmeasured AD pathology will be randomly distributed
between study arms. However, the use of AD markers
should still be considered when the trial intervention is
expected to interact with AD pathology such that it may be
more or less effective when AD pathology is present.
A criticism of some past trials is that improved outcomes
may have been solely due to unmeasured effects on AD
pathophysiology in patients with mixed dementia. Using
vascular monitoring biomarkers could help to avoid this
criticism by demonstrating that the intervention positively
inﬂuenced vascular biomarker outcomes.
Outcome Selection
Outcomes should be prespeciﬁed and should reﬂect the
putative mechanisms targeted by the intervention. Deﬁnitive,
phase 3 trial outcomes should include measures of both
cognition and daily function, including activities of living.52
These outcomes should be sensitive to the effects of the
intervention, disease stage, and duration of treatment. The US
Food and Drug administration has outlined a path to
accelerated preliminary approval of medications targeting
early-stage AD, before dementia, when beneﬁcial effects on
cognition are demonstrated.52 We propose that a similar
approval strategy would also be appropriate for trials in VCI
without dementia.
Cognitive outcomes should include measures of executive
function. In particular, executive dysfunction is the hallmark of
cerebral small vessel disease.5 Cognitive batteries designed
to elicit the deﬁcits in memory and orientation attributable to
AD may lack sensitivity in VCI.53 The Canadian Stroke
Network and National Institute of Neurological Disorders
and Stroke have published harmonization standards for VCI
research that include suggestions for neuropsychological test
batteries of varying length based on criteria including
psychometric qualities, portability, cost, ease of use, domain
speciﬁcity, cross-cultural capability, and lack of ﬂoor and
ceiling effects.54
Secondary outcomes should be selected based on the trial
population and presumed mechanism of action of the
intervention, but may include neuropsychiatric symptoms,
global clinical impression, caregiver burden, or healthcare
utilization. Neuropsychiatric symptoms may appear early and
be associated with risk for progressive cognitive decline or
incident dementia.55 Apathy, depression, psychosis, and
agitation are common neuropsychiatric symptoms in VCI.6
Trial duration should be sufﬁcient to show durable effects.
Six months is probably sufﬁcient for deﬁnitive trials of
cognitive-enhancing interventions (as in the cholinesterase
inhibitor trials) but longer durations will probably be required
for trials aimed at preventing disease progression.
To date, no trials have aimed to prevent progression to
dementia in patients with vascular MCI. However, trials to
prevent progression to dementia may need to be large and of
long duration. Two cohort studies have investigated the risk
for progression to dementia in patients with VCI not
demented. In the clinic-based Canadian Cohort Study of
Cognitive Impairment and Related Dementias (ACCORD), 10/
25 (40%) of patients with VCI not demented converted to
dementia after 2 years.56 In the population-based Canadian
Study on Health and Aging, 58 of 126 participants (46%) with
VCI not demented progressed to dementia over 5 years of
follow-up.57 More contemporary, longitudinal studies are
needed on the natural history of vascular MCI,58 including
the rate of progression to dementia and risk factors for
progression.
Biomarkers
Whenever feasible, biomarkers should be used to identify
target diseases and mechanisms and whether the intervention
is acting on its target. Such biomarkers are especially useful
in early-phase trials to discriminate promising from less
promising candidates to move forward to later-phase trials.
For example, MRI arterial spin label perfusion imaging would
be a useful marker of the effect of agents designed to
increase cerebral blood ﬂow. Although biomarkers can take
many forms, including genetics and ﬂuid markers,59 neu-
roimaging currently appears to be the most promising method
for detecting cerebrovascular injury that contributes to risk
for VCI.12
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Monitoring biomarkers can be used serially to detect
changes in the degree or extent of disease.60 In longer-
duration trials aimed at preventing progression of cerebral
small vessel disease, follow-up MRI could identify interven-
tion-related differences in accrual of clinically hard to detect
cerebrovascular disease including silent infarction and WMH
progression. Because it can be measured quantitatively,
differences in WMH progression and white matter tract
connectivity can be detected with relatively small sample
sizes.61,62 WMH measurement has already been incorporated
as a monitoring biomarker in several RCTs in cardiovascular
disease.63–67 However, limitations of WMH as a biomarker
include a relatively weak association with cognition,62 insen-
sitivity to early microstructural changes associated with
cerebrovascular disease,68 and lack of clarity with regard to
its pathogenesis. For example, in the Action to Control
Cardiovascular Risk in Diabetes Memory in Diabetes study
(ACCORD-MIND), intensive glucose control was associated
with increased, not decreased WMH progression for unclear
reasons.65 Newer candidate neuroimaging markers include
microinfarcts, perivascular spaces, microbleeds, and diffusion
tensor imaging of white matter microarchitecture and brain
connectivity.12
To be considered a surrogate end point, a biomarker must
be an indicator of pathogenic processes that strongly predict
clinical response such that the biomarker change could
substitute for a direct measure of how a patient feels,
functions, or survives.60 Validation of a biomarker for this
purpose requires strong data with a clear mechanistic
rationale and strong evidence that the effect on the surrogate
predicts clinical beneﬁt.69 To date, there is no validated
surrogate end point for VCI trials. Unfortunately, the associ-
ation between WMH progression and progressive cognitive
decline is probably too weak for it to be considered a
surrogate end point.61,62 However, this should not preclude
the use of WMH progression as a monitoring biomarker to
identify early changes in disease progression.
Trial Design
The next generation of VCI trials should use modern designs
including trial registration, prespeciﬁed primary outcomes,
blinding (where possible), intent-to-treat analyses, and rigor-
ous randomization and allocation concealment. After a period
of privileged access by the trial investigators, de-identiﬁed
individual patient data should be uploaded to a repository for
access by the entire research community.70 Adherence to
harmonization standards for VCI research54 will facilitate
individual patient data meta-analysis. If patient subgroups are
deﬁned consistently using harmonized data elements, then
patient information could be combined from multiple trials,
amounting to a fairly large sample size that may tentatively
identify subgroups with positive results. Trial reporting should
adhere to Consolidated Standards of Reporting Trials.71
Ultimately, it is likely that VCI treatment will include a
combination of adherence to conventional vascular risk
reduction, lifestyle modiﬁcation, cognitive enhancement, and
potentially pharmacological treatment to ameliorate or
restore pathobiological changes in the diseased neurovascu-
lar unit. Such treatment may be similar to the multifactorial
intervention that successfully improved cognitive performance
in the Finnish Geriatric Intervention Study to Prevent Cogni-
tive Impairment and Disability study.72 Future trials in VCI
patients should explore the efﬁcacy of such multifaceted
interventions, potentially using factorial designs to identify
additive versus interactive effects of different treatment arms.
New Targets for Treatment
Finally, future trials should exploit advances in the under-
standing of the pathobiology of the neurovascular unit. There
is no clear consensus on the most promising molecular target:
recent studies have investigated diverse pathophysiological
mechanisms including vascular oxidative stress, inﬂammation,
immune trafﬁcking, blood–brain barrier permeability, vascular
beta-amyloid, neurovascular signaling, trophic coupling,
perivascular and vascular solute clearance, and others.10
Animal models have been developed that reproduce speciﬁc
aspects of human VCI syndromes and diseases including
chronic forebrain ischemia, chronic hypertension, and cere-
bral amyloid angiopathy.73 These models are being used to
screen drugs for beneﬁcial effects. Further reﬁnement of
these models and the development of ex vivo experimental
systems could in the future allow more efﬁcient screening of
drug libraries for effects on pathobiological mechanisms.
Conclusions
There are no proven treatments to reduce the risk of
progressive cognitive and functional decline in VCI patients.
Cholinesterase inhibitors provide modest cognitive beneﬁt
but the effect appears to be less than that seen in AD
patients with inconsistent ﬁndings on activities of living,
physician and caregiver impression, and behavior. A large
number of other compounds have been tested in small-scale
early-phase RCTs but have not advanced to later-phase
trials. Promising candidates for advancement are difﬁcult to
discern because of trial methodological limitations that
confer high risk for biased, false-positive results. However,
advances in diagnosis, neuroimaging, trial methods, and
harmonization standards for VCI research suggest that there
is more fertile ground for a new generation of trials to
improve outcomes in VCI, the second most common
contributor to dementia.
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